JP7747521B2 - 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 - Google Patents

尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Info

Publication number
JP7747521B2
JP7747521B2 JP2021557924A JP2021557924A JP7747521B2 JP 7747521 B2 JP7747521 B2 JP 7747521B2 JP 2021557924 A JP2021557924 A JP 2021557924A JP 2021557924 A JP2021557924 A JP 2021557924A JP 7747521 B2 JP7747521 B2 JP 7747521B2
Authority
JP
Japan
Prior art keywords
fgfr3
fgfr
erdafitinib
fgfr2
alterations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527189A (ja
JP2022527189A5 (https=
Inventor
アヴァダニ，アンジャリ，ナラヤン
オハガン，アン，エリザベス
サンティアゴ－ウォーカー，アデミ，エレナ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2022527189A publication Critical patent/JP2022527189A/ja
Publication of JP2022527189A5 publication Critical patent/JP2022527189A5/ja
Priority to JP2025072308A priority Critical patent/JP2025156297A/ja
Application granted granted Critical
Publication of JP7747521B2 publication Critical patent/JP7747521B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
JP2021557924A 2019-03-29 2020-03-27 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 Active JP7747521B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025072308A JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19166428.3 2019-03-29
EP19166428 2019-03-29
EP19188971 2019-07-30
EP19188971.6 2019-07-30
PCT/US2020/025166 WO2020205493A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025072308A Division JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2022527189A JP2022527189A (ja) 2022-05-31
JP2022527189A5 JP2022527189A5 (https=) 2023-04-03
JP7747521B2 true JP7747521B2 (ja) 2025-10-01

Family

ID=70296138

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557924A Active JP7747521B2 (ja) 2019-03-29 2020-03-27 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JP2025072308A Pending JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025072308A Pending JP2025156297A (ja) 2019-03-29 2025-04-24 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Country Status (15)

Country Link
US (1) US20220054484A1 (https=)
EP (1) EP3946341A1 (https=)
JP (2) JP7747521B2 (https=)
KR (1) KR20210145211A (https=)
CN (1) CN113645974A (https=)
AU (1) AU2020253827B2 (https=)
BR (1) BR112021019446A2 (https=)
CA (1) CA3130460A1 (https=)
IL (1) IL286729A (https=)
JO (1) JOP20210266A1 (https=)
MA (1) MA55522A (https=)
MX (1) MX2021011926A (https=)
PH (1) PH12021552342A1 (https=)
SG (1) SG11202109902SA (https=)
WO (1) WO2020205493A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719420A1 (en) * 2023-05-24 2026-04-08 Janssen Pharmaceutica NV Treatment of locally advanced or metastatic urothelial carcinoma with erdafinitib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529090A (ja) 2014-09-26 2017-10-05 ヤンセン ファーマシューティカ エヌ．ベー． Ｆｇｆｒ阻害剤による治療に応答性であるがん患者を同定する際の、ｆｇｆｒ変異遺伝子パネルの使用
JP2020505425A (ja) 2017-02-06 2020-02-20 ヤンセン ファーマシューティカ エヌ．ベー． 癌治療
JP2020506945A (ja) 2017-02-06 2020-03-05 レーニア セラピューティクス インコーポレイテッド がんの治療のための方法、組成物及びキット

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US10208024B2 (en) * 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
TWI798199B (zh) * 2017-02-06 2023-04-11 比利時商健生藥品公司 癌症治療
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529090A (ja) 2014-09-26 2017-10-05 ヤンセン ファーマシューティカ エヌ．ベー． Ｆｇｆｒ阻害剤による治療に応答性であるがん患者を同定する際の、ｆｇｆｒ変異遺伝子パネルの使用
JP2020505425A (ja) 2017-02-06 2020-02-20 ヤンセン ファーマシューティカ エヌ．ベー． 癌治療
JP2020506945A (ja) 2017-02-06 2020-03-05 レーニア セラピューティクス インコーポレイテッド がんの治療のための方法、組成物及びキット

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology，2018年，Vol. 29, Supplement 8，pp. viii327-viii328, 920TiP
Cancer Sci.，2017年，108(2)，pp.236-242
J. Clin. Oncol.，2015年，33(30)，pp.3401-3408，DOI: 10.1200/JCO.2014.60.7341
JCO precision oncology，2018年，Vol. 2，page.1-6，DOI: https://doi.org/10.1200/PO.18.00117

Also Published As

Publication number Publication date
PH12021552342A1 (en) 2022-08-22
MA55522A (fr) 2022-02-09
IL286729A (en) 2021-10-31
EP3946341A1 (en) 2022-02-09
AU2020253827A1 (en) 2021-09-30
JOP20210266A1 (ar) 2023-01-30
KR20210145211A (ko) 2021-12-01
JP2025156297A (ja) 2025-10-14
CN113645974A (zh) 2021-11-12
WO2020205493A1 (en) 2020-10-08
BR112021019446A2 (pt) 2021-11-30
US20220054484A1 (en) 2022-02-24
CA3130460A1 (en) 2020-10-08
AU2020253827B2 (en) 2026-01-08
SG11202109902SA (en) 2021-10-28
JP2022527189A (ja) 2022-05-31
MX2021011926A (es) 2021-11-03

Similar Documents

Publication Publication Date Title
AU2020253054B2 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
US20230110113A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
TWI863962B (zh) 癌症治療
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
HK40126446A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EA052400B1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
KR20250148646A (ko) 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240326

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250918

R150 Certificate of patent or registration of utility model

Ref document number: 7747521

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150